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Abstract
Background
Bacteroides uniformis CECT 7771 is a potential probiotic strain, originally isolated from the
stools of healthy breast-feed infants. The strain showed pre-clinical efficacy in a mouse obe-
sity model. The objective of this study was to evaluate its potential toxicity and translocation
ability after acute oral administration to mice.
Methods and Findings
A safety study was conducted in immunocompetent and immunosuppressed C57BL-6 mice.
Both mouse groups (n = 10 per group) were fed orally 2 x 109 colony forming units (cfu)/day
of B. uniformisCECT 7771 or placebo by gavage for 6 days. Throughout this time, feed and
water intake and body weight were monitored. Afterwards, mice were sacrificed and biologi-
cal samples were collected to analyze blood and urine biochemistry, inflammatory and
immunemarkers; gut mucosal histology and bacterial translocation to peripheral tissues. The
results demonstrated that acute ingestion of this Bacteroides strain had no adverse effects
on the animals’ general health status or food intake, nor did it affect biochemical indicators of
liver, kidney and pancreatic function or gut mucosal histology. Findings also demonstrated
that administration did not lead to bacterial translocation to blood, liver or mesenteric lymph
nodes. B. uniformisCECT 7771 also downregulated gene and protein expression (iNOS and
PPAR-γ) and inflammatory cytokines induced by immunosuppression.
Conclusions
The findings indicate that the acute oral consumption of B. uniformis CECT 7771 does not
raise safety concerns in mice. Further studies in humans should be conducted.
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Introduction
Our understanding of the role played by the gut microbiota in health and disease has burgeoned
thanks to the development of next generation sequencing techniques [1]. To identify associa-
tions with our health status and lifestyle, such techniques are being used to investigate the
microbial structure and function in different body parts, as well as the relationships between the
microbiota and the environment (e.g. diet, antibiotic intake, etc.), and with host genetic and
phenotypic factors (age, diseases, etc.). This information will help us identify new bacterial spe-
cies and strains, beyond those known as traditional probiotics (e.g. Lactobacillus spp., Bifidobac-
terium spp.), which may be used to reduce disease risk and optimize our physiological functions
[2–4]. These new species and strains are normal inhabitants of the human intestinal tract but,
unlike traditional probiotics [5–7], they lack a history of safe use as part of the human diet.
Therefore, a specific safety assessment should guarantee their unambiguous safety status accord-
ing to their intended use [8, 9]. These new bacterial isolates constituting the so-called next-gen-
eration of potential probiotics could, however, be considered as novel foods. Novel foods are
defined as those that have not been substantially consumed in the EU prior to 15 May 1997
according to the Regulation 285/97/EC [10]. Based on this Regulation, the competent authority
in the member state, the EFSA, and the European Commission (EC) make assessments to guar-
antee the safety of any food or food ingredient that has no history of safe use.
The genus Bacteroides represents between 20% and 40% of the human adult colonic bacte-
ria, exceeding by far (by a factor of 10,000) Lactobacillus and Bifidobacterium [11]. Therefore,
this genus and its specific components may presumably play an important role in the gut ecol-
ogy and human health. However, potential exploitation of this genus as a probiotic is in the
early stages.
Species and strains of the genus Bacteroides are known to have desirable traits and proper-
ties including the ability to (i) metabolize complex carbohydrates and generate short-chain
fatty acids directly or via cross-feeding mechanisms (e.g., propionic and butyric acids), which
may have positive effects on satiety and glucose metabolism [3–12]; (ii) outcompete pathogens
by colonization resistance [13] and (iii) optimize the systemic Th1/Th2 balance and induce
regulatory T cell differentiation, favoring tolerance and reducing autoimmune disorders
according to murine studies [14]. Nevertheless, strains of the species Bacteroides fragilismay
also produce toxins, potentially constituting opportunistic pathogens involved in infections
and in chronic inflammatory disorders [15].
Abundance of the species Bacteroides uniformis is higher in breast-fed than in formula-fed
infants [16]. In particular, the strain B. uniformis CECT 7771 was originally isolated from
stools of healthy breast-fed infants [16]. It was selected for its ability to induce in-vitro anti-
inflammatory cytokine production, and to ameliorate the metabolic and immune dysfunction
of diet-induced obesity in mice. B. uniformis CECT 7771 reduced body weight gain, liver stea-
tosis and liver cholesterol, and triglyceride levels in high-fat diet (HFD) fed mice. This strain
also decreased serum glucose, insulin and leptin concentrations [3].
The aim of this study is to provide a preliminary evaluation of the safety and tolerability of
B. uniformis CECT 7771 by short-term (acute) oral administration to normal and immuno-
compromised mice, assessing the general health status, bacterial translocation and different
biochemical and immune markers.
Materials and Methods
Bacterial strain and culture conditions
Bacteroides uniformis CECT 7771 was isolated from stools of healthy infants [16] and depos-
ited in the Spanish Culture Collection (CECT). The bacteria were grown in Schaedler medium
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without hemin broth at 37°C in microaerophilic conditions (AneroGen; Oxoid, Basingstoke,
UK). Cells were harvested by centrifugation (6000 g for 15 min), washed twice in phosphate
buffered saline (PBS, 130 mM sodium chloride, 10mM sodium phosphate, pH7.4). Cells were
then re-suspended in 10% skimmed milk for animal trials. Aliquots of these suspensions were
frozen in liquid nitrogen and stored at -80 C until use. After freezing and thawing, live cells
numbers were determined by colony-forming unit (CFU) counting on Schaedler agar medium
after 48 h incubation. For the strain tested, more than 90% cells were alive upon thawing and
no significant differences were found during storage time (2 months). One fresh aliquot was
thawed for every new experiment to avoid differences in culture viability.
Acute toxicity study in immunocompetent and immunosuppressed mice
The acute toxicity study was basically performed according to Chenoll et al. [17] in 6–7 week-
old male C57BL-6 mice (Harlan Laboratories, Barcelona, Spain) in specific pathogen-free con-
ditions. During the adaptation period (7 days), five animals were housed in each stainless-steel
cage in a temperature-controlled (23°C) room with a 12-h light/dark cycle and 40–50% relative
humidity. All animals received a standard diet. Then, mice were randomly divided in four
groups (n = 10 mice per group) as follows: 1) a group receiving a daily dose of placebo (10%
[w/v] skimmed milk) (Control); 2) a group receiving a daily dose of 2x109 CFU B. uniformis
CECT 7771 by gavage (Control+B); 3) an immunodepressed group receiving a daily dose of
placebo (IMM); and 4) an immunodepressed group receiving a daily dose of 2x109 CFU B. uni-
formis CECT 7771 by gavage (IMM+B). Immunosuppression was induced by intraperitoneal
administration of cyclophosphamide (250 mg/kg), 5 d prior to the intervention with the bacter-
oides strain and a second dose (40 mg/kg) after 3 days of intervention. The mice were kept
inside containment units under positive pressure. Mortality and morbidity were recorded twice
daily and individual body weights were recorded at the beginning and end of the trial. After the
6-day intervention, animals were anesthetized; blood was collected by aortic puncture from
each mouse, which was then immediately killed by cervical dislocation. Large and small intes-
tine, liver and mesenteric lymph nodes (MLN) were removed in sterile conditions, weighed
and stored for different analyses as described below. All procedures involving animals were
specifically approved by the ethics committee of the University of Valencia (Animal Produc-
tion Section, Central Service of Support to Research [SCSIE], University of Valencia, Spain)
and authorized by Dirección General de Agricultura, Ganadería y Pesca (Generalidad Valenci-
ana” (approval ID A 1370964610964).
Bacterial translocation
Bacterial translocation was assessed in samples of blood, liver and MLN. Samples were homog-
enized in buffered peptone water (1g/ml) and 100 μl of the resulting homogenates were inocu-
lated in plates for bacterial counting, using Schaedler agar (Oxoid, UK) for Bacteroides and
Wilkins- Chalgren anaerobe agar (Oxoid, agar) for total anaerobe quantification after incuba-
tion at 37°C in anaerobic conditions (AneroGen; Oxoid, Basingstoke, UK) for 3 days. The
results are expressed as incidence of translocation in the event of positive growth on agar plates,
even a single colony of any microorganism. Data of CFU/ g tissue are also given.
Determination of total IgA and cytokine concentrations
IgA and IL-1β, IL6, IL10, TNF-α and IFN-γ cytokines were quantified in serum by Luminex
assay using simplex kits for each immune parameter and ProcartaPlex Basic Mouse kits (eBios-
cence, Vienna, Austria). The parameters were measured in a Luminex 100 IS™ (Luminex
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Corporation, Madison, USA) in the Central Service of Support to Research [SCSIE], University
of Valencia, Spain.
Cytokine concentrations were also quantified in jejunum samples using the Luminex assay.
Samples of jejunum were homogenized in PBS buffer (pH 7.2) with protease inhibitors cocktail
(Complete, Mini tablets, Roche life science, Mannheim Germany) and, after centrifugation
(10.000 rpm, for 15 min at 4°C), the supernatant was used for cytokine determinations. These
measurements were done in triplicate for each sample.
Biochemical parameter analysis
Biochemical parameters were quantified in serum obtained by blood centrifugation (3000 rpm
for 10 min at room temperature). The following enzymatic assay kits were used: alkaline phos-
phatase (ALP] Reagent, Fisher Diagnostics, Middletown, USA) and Alanine aminotransferase
(ALT) and Amylase (BioVision Incorporated, Milpitas, USA).
Urine was collected before (time = 0) and after 6 days of treatment to determine urea and
creatinine concentrations by enzymatic assay kits (Sigma-Aldrich, St.Louis, USA). Protein con-
centrations were measured by Bradford colorimetric assay (Bradford BIO-RAD, BIORAD,
USA). These measurements were taken in triplicate for each sample.
Histology and histometry
Sections of both the jejunum and colon were collected from each animal immediately after the
sacrifice. Samples from five animals per group were immediately fixed in 4% para-formalde-
hyde in 0.01M phosphate-buffered saline (PBS) pH 7.4 for 24h at 4°C, dehydrated in a graded
series of ethanol, cleared with xylene and embedded in paraffin. Serial microtome sections
(3 μm-thick) were obtained from each sample and stained with haematoxylin/eosin (HE) to
evaluate the structural aspects of both jejunum and colon, and for histometry. For histometry,
the HE-stained sections were assessed to determine the goblet cells per intestinal villi, entero-
cyte height, height of intestinal villi (V) (10 villi measured per section), the depth of intestinal
crypts (C) (10 crypts measured per section), and the villi and crypt ratio values. In addition, the
gut associated lymphoid tissue (GALT) was examined, particularly the lymphoid area of indi-
vidual follicles containing the Peyer’s patches on HE-stained colon sections. Measurements
were taken from images obtained using a light microscope fitted with a NIKON, Olympus,
Eclipse 90i, UK camera using NIS Elements BR 2.3 research software (Kingston; Surrey, KT2
5PR, England). Data are expressed as means and standard error of the mean. All intestinal tis-
sue samples were examined for histological evidence of abnormality by an experienced
histopathologist.
RNA extraction and quantitative real time-PCR analysis
Total RNA from colon and liver was extracted with TRIzol reagent (Molecular Research Cen-
ter, Inc.) and it was purified using the PureLink Total RNA Purification System (Invitrogen)
following the manufacturer's instructions. All RNA samples inside the purification column
were treated with RNase-Free DNase for removal of contaminating DNA (Invitrogen). Purified
total RNA was stored at– 80°C until used as a template for cDNA synthesis. The total RNA was
submitted to electrophoresis on 1% agarose gel to evaluate quality before quantification by
spectrophotometry in a NanoDrop (Thermo Scientific Inc., Bremen, Germany). Only RNA
samples with>200 μg/mL of RNA and A260/A280 ratio between 1.7 and 2.1 were analyzed.
Total RNA was reverse transcribed in a 20 μL final volume from 300 ng/simple total RNA
(DNA-free) using TaqMan Reverse Transcription Reagent kit (Applied Biosystems) according
to the manufacturer's instructions. The following TaqMan Gene Expression Assays were
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purchased (Applied Biosystems, Barcelona, Spain): iNOS (Assay ID Mm00440502_m1),
PPARγ (Assay ID Mm01184322-m1), TLR4 (Assay ID Mm00445273-m1), TLR2 (Assay ID
Mm00442346-m1), NF-KB (Assay ID Mm00476361-m1), p38 (Assay ID Mm01301009-m1),
CD14 (Assay ID Mm00438094-m1), Myd88 (Assay ID Mm0044338-m1) and β-actin (Assay
ID Mm00607939_s1). Amplifications were carried out in a total volume of 20 μL containing 1x
TaqMan Universal PCRMaster Mix (Applied Biosystems). The amplification program was as
follows: an initial cycle of 20 s at 95°C, followed by 40 cycles of 3 s at 95°C and 30 s at 60°C
using the 7900 HT-Fast Real Time PCR System (Applied Biosystems). The relative differences
in expression between groups were expressed using cycle threshold (Ct) values and the ΔΔCt
method [18] as follows. The Ct values of the genes were first normalized in relation to β-actin
in the same sample. Assuming that the Ct value is reflective of the initial starting copy and that
there is 100% efficiency, a difference of one cycle is equivalent to a twofold difference in start-
ing copy. Five replicas were analyzed per sample, and fold changes were generated for each
sample by calculating 2-DDCT [19].
Extraction of protein andWestern blotting of PPAR-γ and iNOS
Frozen intestinal tissue samples (*200 mg) were homogenized in ice cold RIPA buffer (1 x
solution, 150 mMNaCl, 1.0% IGEPAL1 CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and
50 mM Tris, pH 8.0) (Sigma-Aldrich) and centrifuged at 10000 x g and 4°C for 10 min. Protein
concentration was determined by the Bradford’s method using the commercial kit Bio-Rad
protein assay (Bio-Rad laboratories)
Under denaturing conditions, samples (100 μg of proteins) were resolved by electrophoresis
a 12% dodecylsulfate-polyacrylamide gel (SDS-PAGE) for PPAR-γ detection and in 8%
SDS-PAGE for iNOS detection. The proteins were then transferred onto nitrocellulose Amer-
sham Protran Western blotting membrane.
PPAR-γ was detected by a rabbit polyclonal antibody against amino acids 8–106 of PPAR-γ
(sc-7196, Santa Cruz Biotechnology, Inc). iNOS was detected by a rabbit polyclonal antibody
against a peptide mapping near the C-terminus of NOS2 (iNOS) of mouse origin (sc-650,
Santa Cruz Biotechnology, Inc). The reaction was visualized by biotinylated secondary anti-
body followed by Amersham ECL select western blotting detection reagent. To control for pro-
tein degradation, the Western analysis was done in parallel for all samples using an antibody
against β-actin (sc-130656, Santa Cruz Biotechnology, Inc).
Statistical analysis
The results were analyzed using GraphPad Prism1 Version 5.0 (Graph Pad Software Inc., San
Diego, CA, USA). All the results are expressed as the mean ± SEM. Two-way analysis of vari-
ance (ANOVA), and repeated measures ANOVA were applied for comparisons of means. Bon-
ferroni test (when the variances were assumed to be equal) or Dunnett’s T3 test (when the
variances were assumed to be unequal) was applied to perform post hoc pairwise multiple com-
parisons between groups. Differences between groups were established using an unpaired Stu-
dent's t-test (data were normally distributed) or Mann-Whitney U test when the data were
non-normally distributed. Significance was defined at P 0.05.
Results
General health, feed and water intake, and growth
Throughout the experimental period, there was no noticeable change in normal activity, behav-
ior, or hair lustre in any of the groups of mice. There were no records of diarrhea or other
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treatment-related sickness or death. At the end of the experimental period, all animals were
alive and healthy in all experimental groups.
There were no statistically significant difference in body weight gain or loss between immu-
nocompetent and immunosuppressed animals treated or untreated with B. uniformis CET
7771 (Table 1).
Concerning tissue weight, there were no significant differences in the weight of liver and
MLN between controls and mice orally administered B. uniformis CET 7771 (Table 1). The col-
oration and appearance of the analyzed tissues was normal, and no differences were observed
between groups.
Bacterial Translocation
The incidence of translocation of bacteria from the gut to different tissues is shown in Table 2
No bacteremia was observed in any of the experimental groups. Although some events of bac-
terial translocation to liver and MLN were recorded, there was no statistically significant differ-
ence in the incidence of these events between control and treated groups, suggesting that they
were due to cross-contamination during animal dissection.
Table 1. Body and tissue weight of control mice and immunosuppressedmice, fed eitherB. uniformis CECT 7771 or placebo.
Body and organs weight Control Control+B IMM IMM+B
Initial Body Weight (g) 20.98 ± 0.31 21.54 ± 0.29 21.44 ± 0.26 21.58 ± 0.30
Final Body Weight (g) 21.98 ± 0.40 22.10 ± 0.29 21.27 ± 0.36 20.80 ± 040
Weight increment (g) 1.07 ± 0.39 0.56 ± 0.23 (-) 0.17 ± 0.75 (-) 0.62 ± 1.33
MLNs (mg) 33.7 ± 0.4 41.8 ± 0.4 35.3 ± 0.3 34.9 ± 0.3
Liver (mg) 975.5 ± 65.3 980.1 ± 120.3 974.3 ± 180.2 983.9 ± 78.3
Control, mouse group fed placebo daily by gavage for 6 days (n = 10); Control+B, mouse group that received a daily dose of 2 x109 CFU B. uniformis
CECT 7771 by gavage for 6 days (n = 10); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days (n = 10); and IMM+B,
immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformis CECT 7771 by gavage for 6 days (n = 10).
MLNs mesenteric lymph nodes
Data are expressed as mean values with SEM, n = 10. Differences between groups were established using an unpaired Student's t-test at p<0.05.
doi:10.1371/journal.pone.0145503.t001
Table 2. Bacterial translocation in MLNs, liver and blood of immunocompetent and immunosuppressedmice, fed either B. uniformis CECT 7771
or placebo.
Body organs Control (n = 10) Control + B (n = 10) IMM (n = 10) IMM + B (n = 10)
Culture media
SCHA WILK SCHA WILK SCHA WILK SCHA WILK
CFU/g* (n° positive samples per group when appropriate)
MLNs 0 0 0 0 0 0 0 0
Liver 3 (5/10) >50 (10/10) 1 (4/10) >50 (10/10) 1 (5/10) >50 (10/10) 0 (10/10) >50 (9/10)
Blood 0 0 0 0 0 0 0 0
Control; Control + B receiving a daily dose of 2 x109 CFU B. uniformis CECT 7771 by gavage for 6 days; IMM, immunosuppressed mice and IMM + B,
immunosuppressed mice group receiving a daily dose of 2 x109CFU B. uniformis CECT 7771 by gavage for 6 days.
MLNs mesenteric lymph nodes
SCHA = Schaedler anaerobe agar, speciﬁcally for Bacteroides spp.
WILK = Wilkins–Chalgren agar, for strict anaerobic bacteria
*Data are expressed as colony forming unit (cfu) per gram of tissue.
doi:10.1371/journal.pone.0145503.t002
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The number of positive organs and the number of cfu found is consistent with studies pub-
lished previously, where events of cross-contamination eventually lead to detect bacteria in
diverse organs from control animals [5, 20].
Biochemical parameters
In order to detect signs of possible lesions in different organs due to oral bacteroides adminis-
tration, biochemical parameters related to pancreatic, liver and kidney functions were analyzed
(Figs 1 and 2). Oral administration of B. uniformis CECT 7771 did not cause significant
changes in urine parameters (Fig 1) nor in serum amylase activity (Fig 2C) between the differ-
ent mice groups studied. The immunosuppressed treatment induced an increase in ALT activ-
ity of serum, independently of bacteroide administration, although the effect was more
remarkable in the groups receiving the bacteroide due to lower serum levels of the Control+B
group (Fig 2A). The ALP activity was significantly reduced in the bacteroide-fed immunosup-
pressed mice compared to placebo-fed immunosuppressed group (p<0.05). Moreover, when
comparing immunocompetent and immunosuppressed mice we observed that the immuno-
suppression induced a decrease in ALP activity of serum (p = 0.07).
Jejunum and colon mucosal histology effects
The effect of the intervention on jejunum and colon histology is shown in Table 3 and Figs 3
and 4, respectively. In jejunum, immunocompetent and immunosuppressed group showed
slight, but not significant, differences in some of the parameters measured, except for villus
height/crypt depth ratio, which was slightly reduced (p = 0.06) and in the number of goblet
cells/villus ratio (p<0.01) in immunosuppressed mice (Table 3 and Fig 3). However, the immu-
nosuppressed mice treated with the bacteroide showed values of crypts depth and villus height/
crypt depth in the jejunum similar to immunocompetent mice, restoring the alterations caused
by immunosuppression. The Lieberkühn crypts had a uniform and constant appearance (Fig
3). The immunosuppressed mice also showed a significant decrease in crypt depth in colon
compared to control mice; however, effects of bacteroides administration were undetectable
(Table 3). Control mice treated with B. uniformis CECT 7771 exhibited a significant increase in
goblet cells/villus ratio in the colon (p< 0.01) (Table 3, Fig 4, IMM+B) compared to mice fed
placebo.
There were no statistically significant differences in number and size of lymphatic follicles
between immunocompetent and immunosuppressed mice, nor was lymphocytic infiltrate
apparent (Figs 3 and 4).
Immunological effects
As expected, the serum IgA concentration was higher (p = 0.001) in the immunocompetent
mouse groups than in immunosuppressed ones (Fig 5). The concentrations of the cytokines
assayed (IL-1β, IL10, IFNγ IL6 and TNF-α) were below the detection limit in serum (data not
shown). In jejunum samples IL-1β, IL10 and IFN-γ concentrations were detected (Fig 6), but
no statistical differences were found between the four experimental groups for IL-1β, and IL10
(Fig 6A and 6B). In contrast, immunosuppressed mice had higher IFN-γ concentrations than
immunosuppressed mice fed B. uniformis CECT 7771 in jejunum samples (Fig 6C).
Gene expression effects in colon and liver
Gene expression comparison between immunosuppressed mice and immunocompetent mice
fed B. uniformis CECT 7771 (IMM+B) or placebo (IMM) are shown in Figs 7 and 8.
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Fig 1. Urine biochemistry measurements in immunocompetent and immunosuppressedmice, fed
eitherB. uniformisCECT 7771 or placebo.Control, mouse group fed placebo daily by gavage for 6 days
(n = 10); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformisCECT 7771 by
gavage for 6 days (n = 10); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days
(n = 10); and IMM+B, immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformis
CECT 7771 by gavage for 6 days (n = 10). Data are expressed as means and SEM. The differences were
determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically
significant. Measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g001
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Fig 2. Blood biochemistry measurements in immunocompetent and immunosuppressedmice, fed
eitherB. uniformisCECT 7771 or placebo.Control, mouse group fed placebo daily by gavage for 6 days
(n = 10); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformisCECT 7771 by
gavage for 6 days (n = 10); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days
(n = 10); and IMM+B, immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformis
CECT 7771 by gavage for 6 days (n = 10). Data are expressed as means and SEM. The differences were
determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically
significant. Measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g002
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Gene expression of components of the TLR4 and TLR2 pathways (TLR4, TLR2, CD14,
MyD88, p38 and NF-Κβ genes) did not exhibit significant changes between the four mouse
groups in any of the tissue studied (Figs 7 and 8).
Only PPARγ and iNOSmRNA expression was upregulated in colon and liver of immuno-
suppressed mice compared to control mice. Bacteroides administration downregulated the
increased iNOS and PPARγ gene expression detected in immunosuppressed mice (Fig 7). Liver
immunosuppressed mice also showed increased iNOS expression (p<0.05) and this effect was
reversed by the Bacteroides strain tested (Fig 8).
PPARγ and iNOS protein expression in colon
As shown in the Western blot of colon fractions (Fig 9), immunosuppression treatment
increased PPARγ and iNOS protein expression in mice compared to controls. In contrast, the
Bacteroides administration ameliorated those effects on PPARγ and iNOS protein expression
detected in immunosuppressed mice (Fig 9A and 9B, respectively). This analysis confirmed
results obtained by gene expression analysis (Fig 7)
Discussion
The majority of commercialized probiotics (classical probiotics) are still restricted to lactic acid
bacteria, such as the genera Lactobacillus, as well as to bifidobacteria, isolated from biological
samples and often derived from fermented foods owing to their safety status based on their
long history of consumption in traditional fermented products without causing concerns [21].
However, other indigenous species and strains that are dominant inhabitants of the human
intestine could constitute a next generation of probiotics with improved efficacy [1]. In fact,
Table 3. Gut mucosal histologymeasurements of immunocompetent and immunosuppressedmice, fedB. uniformisCECT 7771 or placebo.
Control (n = 5) Control + B (n = 5) IMM (n = 5) IMM + B (n = 5)
Jejunum
pa pb pc
Villus height (μm) 290.21 ± 18.74 278.21±15.64 >0.05 246.10±23.27 >0.05 253.3± 18.03 > 0.05
Crypt depth (μm) 58.39 ±9.23 65.48 ± 2.46 >0.05 67.76±3.55 >0.05 57.04 ± 2.24 < 0.05
Villus width (μm) 37.42 ± 3.23 35.47 ± 2.24 >0.05 45.80 ±5.63 >0.05 38.54 ± 2.53 >0.05
Villus height/crypt depth ratio 4.50 ± 0.44 4.49 ± 0.36 >0.05 3.71 ± 0.34 = 0.06 4.70 ± 0.46 = 0.06
Number of goblet cells/villus 11 (10–12) 8 (6–11) >0.05 4 (3–5) <0.01 4 (3–5) >0.05
Enterocyte height (μm) 12.95± 0.77 13.48±0.89 >0.05 12.41±0.58 >0.05 11.45±0.59 >0.05
Enterocyte:lymphocyte ratio 4:1 5:1 >0.05 4:1 >0.05 5:1 >0.05
Colon
pa pb pc
Crypt depth (μm) 94.98± 46.97 91.91 ± 38.44 >0.05 64.57 ± 18.54 = 0.012 76.88 ± 29.57 >0.05
Number of goblet cells/villus 7 (6–14) 16 (13–18) < 0.01 8 (5–16) >0.05 10 (5–11) >0.05
Control, mouse group that received placebo by gavage for 6 days; Control+B, group that received a daily dose of 2 x1019 CFU B. uniformis CECT 7771
by gavage for 6 days; IMM, immunosuppressed mouse group that received placebo by gavage for 6 days and IMM+B, immunosuppressed mouse group
that received a daily dose of 2x109 CFU B. uniformis CECT 7771 by gavage for 6 days.
a Control vs Control+B,
b Control vs IMM
c IMM vs IMM+B
Data are expressed as mean values with SEM, n = 5 samplesx10measures. Signiﬁcant differences were established at p<0.05 by using t-student test.
doi:10.1371/journal.pone.0145503.t003
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80–90% of bacterial phylotypes are members of two phyla: Bacteroidetes (including the genera
Bacteroides and Prevotella) and Firmicutes [22]. Relative proportions of Firmicutes and Bacter-
oides have been related to the host metabolic phenotype (e.g. lean and obese). Within this phy-
lum, the genus Bacteroides or subgroups have also been associated with a lean phenotype or
weight loss in observational human studies, although contradictions exist in the literature [23].
Breast-feeding also seems to increase the abundance of B. uniformis in the fecal microbiota of
healthy infants [1, 16], as compared to formula-feeding; furthermore, breast-feeding reduces
the risk of developing obesity and type-2 diabetes [24]. Therefore, a strain of this species, B.uni-
formis CECT 7771, was selected among other human infant Bacteroides strains for its anti-
inflammatory potential in vitro and evaluated in mice with high-fat-diet induced obesity [3].
The administration of B. uniformis CECT 7771 ameliorated diet-induced metabolic and
immune dysfunction associated with intestinal dysbiosis in obese mice. In the light of this evi-
dence, and given the potential use of this strain for obesity management in humans, here we
evaluated its safety by monitoring acute daily intake in immunosuppressed and immunocom-
petent mice.
There are no general guide-lines for safety evaluation of new strains to be considered as
potential probiotics; however, rodent studies of acute oral toxicity have been proposed as a
basic test for the assessment of probiotic safety [25] and applied previously in safety assessment
studies [5,20–26]. The oral toxicity assessment showed that mice treated with a high dose of
Fig 3. Histology of jejunum sections from immunocompetent and immunosuppressedmice, fed eitherB. uniformisCECT 7771 or placebo.Control,
mouse group fed placebo daily by gavage for 6 days (n = 5); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformis CECT 7771 by
gavage for 6 days (n = 5); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days (n = 5); and IMM+B, immunosuppressedmouse
group receiving a daily dose of 2 x109CFU B. uniformis CECT 7771 by gavage for 6 days (n = 5). Data are expressed as means and SEM. The differences
were determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically significant. These measurements were
taken in 10 fields for each sample. Photomicrographs 4x of representative HE-stained slides are shown. V = Villi and C = crypt.
doi:10.1371/journal.pone.0145503.g003
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the potential probiotic strain B. uniformis CECT 7771 were healthy after daily oral administra-
tion for 6 days. This relative dose is 100 times higher than in humans when normalized by
body surface area. No adverse effects were observed on body weight, food intake or other gen-
eral indicators of the animals’ health status as a consequence of B. uniformis CECT 7771
administration. Similar results were obtained in immunosuppressed mice with the classical
probiotc strains of the species Lactobacillus rhamnosus, Bifidobacterium longum and Bifidobac-
terium breve [27].
Translocation of bacteria from the intestinal lumen to MLN and other tissues may consti-
tute a risk for systemic infection (bacteremia). Therefore, we assessed translocation of bacte-
rium studied as an indication of potential infectivity and pathogenicity [28]. Although most
Bacteroides spp. are considered commensals some strains of B. fragilis are opportunistic patho-
gens and have been involved in bacteraemia, which also justify to assess translocation of other
bacteroides in a first safety assessment [29]. In spite of the high dose of B. uniformis CECT
7771 used for the feeding trial, no translocation of bacteria to MLN or blood was detected in
the bacteroide-treated groups. Although bacterial counts were eventually found in liver, trans-
location events were similar in mice receiving the potential probiotic and control mice. This
Fig 4. Histology of colon section from immunocompetent and immunosuppressed mice, fed eitherB. uniformis CECT 7771 or placebo.Control,
mouse group fed placebo daily by gavage for 6 days (n = 5); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformis CECT 7771 by
gavage for 6 days (n = 5); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days (n = 5); and IMM+B, immunosuppressedmouse
group receiving a daily dose of 2 x109CFU B. uniformis CECT 7771 by gavage for 6 days (n = 5). Data are expressed as means and SEM. The differences
were determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically significant. These measurements were
taken in 10 fields for each sample. Photomicrographs 20 x of representative HE-stained slides are shown. G, goblet cells; C, crypts.
doi:10.1371/journal.pone.0145503.g004
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fact suggests that translocation was not associated with treatment but with cross-contamina-
tion. The presence of some bacteria in the liver has been described in healthy mice in previous
safety studies [20, 30].
Biochemical parameters were determined in urine and blood to detect potential adverse
sub-clinical effects of the strain tested. Urea, creatinine and protein concentration are routine
markers of kidney function, low levels of urea or creatinine and high levels of protein in urine
may indicate renal failure. The urine parameters were similar in all four mouse groups, suggest-
ing the absence of adverse effects on key organs due to bacteroides administration. ALT and
ALP are indicators of liver function, and amylase of the pancreatic function. We observed that
ALT activity increased slightly in both immunosuppressed groups independently of oral
administration of the bacteroide. Amylase activity was not affected by the either immunosup-
pression or bacteroides administration. The liver is the main organ responsible for the removal
of lipopolysaccharide (LPS) coming from the gut from the circulation, which may have adverse
health consequences. In this context, ALP plays an important role by dephosphorylating LPS
which induces a 100-fold reduction in lipid A toxicity [31]. In our study, the ALP activity
Fig 5. Themeasurement of serum IgA concentration in immunocompetent and immunosuppressedmice, fed eitherB. uniformisCECT 7771 or
placebo.Control, mouse group fed placebo daily by gavage for 6 days (n = 10); Control + B, mouse group that received a daily dose of 2 x109 CFU B.
uniformisCECT 7771 by gavage for 6 days (n = 10); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days (n = 10); and IMM+B,
immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformis CECT 7771 by gavage for 6 days (n = 10). Data are expressed as
means ± SEM. The differences were determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically significant.
These measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g005
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Fig 6. Cytokine production in jejunum samples from immunocompetent and immunosuppressed
mice, fed eitherB.uniformisCECT 7771 or placebo. Control, mouse group fed placebo daily by gavage for
6 days (n = 10); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformis CECT 7771
by gavage for 6 days (n = 10); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days
(n = 10); and IMM+B, immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformis
CECT 7771 by gavage for 6 days (n = 10). Data are expressed as means ± SEM. The differences were
determined by applying the Mann-Whitney U test. In every case, p-values <0.05 were considered statistically
significant. These measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g006
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showed a slight decrease in immunosuppressed mice treated with B. uniformis CECT 7771
compared to immunosuppressed mice fed placebo, which would suggest that the bacteroides
reduces endotoxemia in immunocompromised mice although differences were not statistically
significant to draw conclusions in this regard.
Fig 7. Gene expression assays in colon from immunocompetent and immunosuppressedmice, fed eitherB.uniformis CECT 7771 or placebo.
Control, mouse group fed placebo daily by gavage for 6 days (n = 5); Control + B, mouse group that received a daily dose of 2 x109 CFU B. uniformisCECT
7771 by gavage for 6 days (n = 5); IMM, immunosuppressedmouse group fed placebo daily by gavage for 6 days (n = 5); and IMM+B, immunosuppressed
mouse group receiving a daily dose of 2 x 109CFU B. uniformisCECT 7771 by gavage for 6 days (n = 5). Data are expressed as the mean value ± SEM.
Differences between groups were established using an unpaired Student's t-test. Results with a two-sided p-value <0.05 were considered statistically
significant. These measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g007
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Fig 8. Liver gene expression assays in immunocompetent and immunosuppressedmice, fed eitherB.
uniformis CECT 7771 or placebo.Control, mouse group fed placebo daily by gavage for 6 days (n = 5);
Control + B, mouse group that received a daily dose of 2 x 109 CFU B. uniformisCECT 7771 by gavage for 6
days (n = 5); IMM, immunosuppressed mouse group fed placebo daily by gavage for 6 days (n = 5); and
IMM+B, immunosuppressed mouse group receiving a daily dose of 2 x109CFU B. uniformisCECT 7771 by
gavage for 6 days (n = 5). Data are expressed as the mean value ± SEM. Differences between groups were
established using an unpaired Student's t-test. Results with a two-sided p-value <0.05 were considered
statistically significant. These measurements were taken in triplicate for each sample.
doi:10.1371/journal.pone.0145503.g008
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The intestinal mucosa has an important barrier function, preventing potential pathogens
and toxigenic substances from invading other tissues systemically [5, 30]. In this study, oral
administration of B. uniformis CECT 7771 did not reveal any adverse effects on the integrity of
the gut mucosa. However, immunosuppression caused a statistically significant decrease in the
number of goblet cells in the jejunum and in crypt width in the colon, and a slight reduction in
villus height/crypt depth ratio in the jejunum compared to controls. By contrast, the adminis-
tration of the bacteroides to immunosuppressed mice reversed the reduced villus height/crypt
depth ratio; moreover, the other alterations seen in immunosuppressed mice were unaffected.
Administration of B. uniformis CECT 7771 also increased the number of goblet cells in the
colon, which could enhance the production of the mucus coating antigens and pathogens and
constituting a first line of defense before immune system activation. Similar observations have
been made when evaluating strains of the genera Bifidobacterium and Propionibacterium [32],
such as Bifidobacterium longum [5].
As specified above, the selection of B. uniformis CECT 7771 was based on previous in vitro
studies demonstrating its ability to induce high levels of anti-inflammatory cytokines, together
with low levels of pro-inflammatory cytokines after stimulation of Raw264.7 macrophages cul-
tures [3]. Also positive effects have been detected in vivo in mice with and without diet-induced
obesity [3]. The present study evaluated the effects of the same strain on a normal and
Fig 9. PPAR-γ and iNOS protein expression in colon from immunocompetent and
immunosuppressedmice, fed eitherB.uniformis CECT 7771 or placebo. (A) PPAR-γ and (B) iNOS
protein expression from colon protein samples were visualized using western blot analysis. Control, mouse
group fed placebo daily by gavage for 6 days (n = 5); Control + B, mouse group that received a daily dose of 2
x109 CFU B. uniformisCECT 7771 by gavage for 6 days (n = 5); IMM, immunosuppressed mouse group fed
placebo daily by gavage for 6 days (n = 5); and IMM+B, immunosuppressed mouse group receiving a daily
dose of 2 x109CFU B. uniformisCECT 7771 by gavage for 6 days (n = 5).
doi:10.1371/journal.pone.0145503.g009
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suppressed immune system to provide further evidence of safety in conditions of increased risk
of translocation and immune reaction. Immunosuppression was evident from the reduced IgA
concentrations in blood, which was not reversed by the bacteroides administration. B. unifor-
mis CECT 7771 reduced concentrations of pro-inflammatory cytokines (mainly IFN-γ and
slightly IL1β) in the jejunum of immunosuppressed mice, which may reduce the development
of inflammatory overreaction in immunocompromised subjects. We also studied the effect of
B. uniformis CECT 7771 on the expression of genes directly involved in bacterial recognition.
TLR pathways play a critical role in the early innate immune response to invading microorgan-
isms or commensals [33]. TLRs recognize highly conserved structural motifs known as patho-
gen-associated microbial patterns (PAMPs) and danger-associated molecular patterns
(DAMPs), which are endogenous molecules released from necrotic or dying cells. Stimulation
of TLRs by the corresponding PAMPs or DAMPs initiates signaling cascades, leading to the
activation of transcription factors, such as AP-1, NF-κβ and interferon regulatory factors
(IRFs) [33]. TLR signaling results in a variety of cellular responses, including the production of
interferons (IFNs), pro-inflammatory cytokines and effector cytokines, which direct the adap-
tive immune response. TLR2 is essential for the recognition of a variety of PAMPs from Gram-
positive bacteria, including bacterial lipoproteins, lipomannans and lipoteichoic acids, while
TLR4 is predominantly activated by lipopolysaccharide (LPS) of Gram-negative bacteria [33,
34]. In particular, epithelial TLR2 activation can protect against barrier disruption [34]. In con-
trast, activation of TLR 4 and NF-Kβ usually lead to an inflammatory response that could also
increase intestinal permeability and enhance bacterial translocation [34]. In all four groups of
mice, none of the tissues showed changes in expression of the genes involved in the TLR path-
way. In addition, our results from the histological, immunological and translocation analyses
are consistent with the absence of inflammatory-response activation, or gut barrier dysfunction
associated with the bacteroides intake.
Finally, the results of this study support our previous study indicating an anti-inflammatory
effect of B. uniformis CECT 7771 in vitro in macrophages [3], as its administration to immuno-
suppressed mice also reduced the IFN-γ concentrations induced in the intestine. Administration
of the bacteroide also reduced the iNOS expression, which was increased in the intestine and
liver of immunosuppressed mice. The inducible isoform of nitric oxide synthases (iNOS) is one
of three key enzymes generating nitric oxide (NO) from the amino acid L-arginine, which is
involved in the immune response, acting as an immune defense mechanism and exerting cyto-
toxic effects at high concentrations. A variety of inflammatory stimuli (cytokines or bacterial
pathogens) can activate iNOS expression, generating high concentrations of NO through the
activation of inducible nuclear factors, including NFkB. For example inflammatory cytokine
release (e.g. IFNγ and IL-1β) may activate NO production by altering the conformation of the
iNOS promoter as in immunosuppressed mice where inflammatory cytokine levels are increased
[35, 36]. In agreement with this mechanism, the administration of the bacteroide, exerting an
anti-inflammatory effect, led to a reduction in both iNOS expression (gene and protein expres-
sion) and IFNγ production. Theoretically, LPS from Gram-negative bacteria, such as Bacteroides
spp., could mediate activation of the TLR4 pathway, leading to MyD88-dependent activation of
NF-κB and triggering a pro-inflammatory response as well as iNOS transcription to exclude
pathogen invasion [35–38]. However, the capsular polysaccharide (PSA) of Bacteroides fragilis
represents a reverse example, where the TLR detection of a microbial ligand via TLR2 promotes
an anti-inflammatory response and immunologic tolerance of this bacterium by the host [39].
This could presumably be the case for B. uniformis, although the exact mechanism by which tol-
erance to this bacterium species is induced needs further investigations.
PPARγ gene and protein expression was also increased in the intestine of immunosup-
pressed mice. This was probably a protective response against the pro-inflammatory intestinal
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milieu caused by immunosuppression, which was also reduced by the bacteroides administra-
tion. In fact, PPARγ is recognized as a fundamental regulator of the immune response due to
its ability to inhibit the expression of inflammatory cytokines and direct the differentiation of
immune cells towards anti-inflammatory phenotypes. However, the administration of B. uni-
formis CECT 7771 reduced PPARγ overexpression in immunosuppressed mice, reaching simi-
lar levels to those found in controls. In this context, Bacteroides thetaiotaomicron has also been
shown to antagonize transcription factor NF-kB and, thereby, exert an anti-inflammatory
effect by enhancing the nuclear export of RelA, a subunit of the transcriptionally active NF-kB,
facilitating its complex with PPARγ [40].
In conclusion, the results of this safety evaluation by acute oral administration of B. unifor-
mis CECT 7771 to mice do not raise safety concerns. No adverse effects were observed regard-
ing general health indicators, bacterial translocation, gut mucosal histology, organ function or
immune markers. Moreover, B. uniformis CECT 7771 administration to immunosuppressed
mice restored the levels of inflammatory cytokines and other immune regulatory genes and
proteins. Further studies are required to confirm tolerability and safety in longer studies in
rodents and, of course, in humans.
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